You've never seen anything like it · Doors open inStarts at 7:00 PM ET
Skip to content

Bioregulator · Cellular research

Livagen

Livagen is the synthetic tetrapeptide Lys-Glu-Asp-Ala (KEDA), a short linear peptide with free amino and carboxyl termini and a molecular mass of 461.5 g/mol.

Compound type
Bioregulator
Research area
Cellular
Formula
C18H31N5O9
Average mass
461.467 Da
Monoisotopic mass
461.2122 Da
Length
4 residues

What it is

Livagen is a synthetic linear tetrapeptide with the sequence Lys-Glu-Asp-Ala, written KEDA in one-letter code and H-Lys-Glu-Asp-Ala-OH in full. It has the formula C₁₈H₃₁N₅O₉, a molecular mass of 461.5 g/mol, CAS number 433257-50-2 and PubChem CID 87919683. It belongs to a set of ultrashort peptides, two to seven residues long, developed within a single research program and grouped as short-peptide bioregulators 1.

The published record on KEDA as a defined molecule is small. Most of what has been reported comes from the research group that first described the sequence, and much of it appeared in Russian-language journals.

Discovery and origin

Livagen comes out of a long-running research program in St. Petersburg, Russia, led by Vladimir Khavinson. The program began with polypeptide fractions extracted from animal organs and later moved to short synthetic peptides whose sequences were modeled on those fractions. KEDA is listed among the program's ultrashort peptides alongside related sequences such as KED and KEDW-NH₂ 1.

The KEDA sequence was derived from amino acid analysis of liver polypeptide preparations, and it was set out in patent filings by the same group. The tetrapeptide itself is made by chemical synthesis, not extracted from tissue.

Structure and chemistry

KEDA is built from four L-amino acids joined by three peptide bonds. Reading from the N-terminus, lysine contributes a basic side-chain amine, glutamic acid and aspartic acid each contribute a side-chain carboxyl group, and alanine contributes a small methyl side chain ahead of the free C-terminal carboxyl. With two acidic side chains, one basic side chain and both termini unblocked, the peptide is highly polar and carries a net charge of about minus one near neutral pH.

The sequence contains no aromatic residues, so it absorbs only weakly at 280 nm, and no cysteine or methionine residues, so it has no sulfur-containing side chains open to oxidation. Its Lys-Glu-Asp motif is shared with other short sequences from the same program 1.

How it is studied in the laboratory

Published laboratory work on KEDA as an isolated molecule is limited, and the sources available are reviews written by the originating group. A 2022 review of ultrashort peptide transport summarized a stability study in which KEDA, alongside the related peptides AEDG, KE and KEDW, was incubated in physiological saline, Ringer's solution and hydrochloric acid, and in homogenates of gastrointestinal, liver, kidney and spleen tissue. Cleavage of the terminal residue was assessed with L-aminopeptidase, and the review reported that KEDA and KEDW resisted hydrolysis for 3 to 4 hours under those conditions 1.

The same review reported a molecular docking analysis in which a series of ultrashort peptides, KEDA among them, were docked into a structural model of the LAT1 L-type amino acid transporter and ranked by a computed binding score (ICM-score). KEDA received a score of −22.01 1. These are computational estimates; the review does not report a measured transport value for KEDA.

In a broader review, the originating group proposed that peptides of two to seven residues can enter cell nuclei and interact with histone proteins and with DNA, including promoter sequences 2. That review synthesizes the group's own earlier work and does not present new data on KEDA.

Analytical notes

Identity is confirmed by mass spectrometry. Calculated from the average molecular mass, the expected singly protonated ion [M+H]⁺ is m/z 462.51 and the doubly protonated ion [M+2H]²⁺ is m/z 231.76. On high-resolution instruments that report monoisotopic values, the neutral monoisotopic mass is 461.21 and the [M+H]⁺ ion falls near m/z 462.22. Sequence isomers such as KDEA share the same formula and mass, so tandem MS with b- and y-ion coverage is needed to confirm residue order.

Purity is assessed by reversed-phase HPLC. With no aromatic residues, detection relies on peptide-bond absorbance near 210 to 220 nm rather than 280 nm. The peptide is very polar and elutes early on C18 columns under acidic water-acetonitrile gradients, so method conditions should retain it clear of the solvent front.

Like most synthetic peptides, KEDA is typically isolated as a salt, commonly with acetate or trifluoroacetate counter-ions. A salt form does not move the peptide ions above, but it does lower the amount of peptide in each milligram of powder, which accounts for any difference between gross and net peptide content on a certificate.

Storage and handling in the laboratory

The product is a lyophilized white powder that is soluble in water. Store the sealed vial at −20 °C, protected from light. Short, highly charged peptides take up atmospheric moisture readily, so allow a cold vial to reach room temperature before opening and reseal it promptly.

Open questions in the literature

Nearly all published work on KEDA comes from the group that introduced the sequence, and the sources reviewed for this profile contain no independent replication of the laboratory findings summarized above 12. No experimentally determined solution structure or conformational study of KEDA was identified. Stability data rest on a single hydrolysis study reported secondhand in a review, and the transporter data are docking scores rather than measured uptake. Peer-reviewed analytical reference data for this sequence, such as published MS/MS spectra or a validated HPLC method, were also not found.

Identity check

A mass-spectrometry result for Livagen should show peaks near these values. A result more than about one unit away is worth a question to the testing lab. Salt forms such as acetate or TFA do not move these peaks, though they do mean less peptide in each milligram of powder.

IonExpected m/z
[M+H]+462.22

References

  1. Khavinson V, Linkova N, Kozhevnikova E, Dyatlova A, Petukhov M. Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers. Int J Mol Sci. 2022;23(14):7733. doi:10.3390/ijms23147733. Source
  2. Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. Molecules. 2021;26(22):7053. doi:10.3390/molecules26227053. Source

For laboratory research use only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any disease.